Neuberger Berman Group LLC Aerie Pharmaceuticals Inc Transaction History

Neuberger Berman Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$18.41 - $28.0 $10.2 Million - $15.5 Million	-552,400 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$28.97 - $48.21 $4.6 Million - $7.66 Million	158,900 Added 40.38%	552,400 $16.3 Million
Q1 2019 May 13, 2019	BUY	$36.32 - $49.25 $254,240 - $344,750	7,000 Added 1.81%	393,500 $18.7 Million
Q4 2018 Feb 12, 2019	BUY	$33.0 - $60.04 $353,100 - $642,428	10,700 Added 2.85%	386,500 $14 Million
Q3 2018 Nov 13, 2018	BUY	$56.15 - $73.9 $1.94 Million - $2.55 Million	34,500 Added 10.11%	375,800 $23.1 Million
Q2 2018 Aug 13, 2018	BUY	$47.85 - $70.45 $995,280 - $1.47 Million	20,800 Added 6.49%	341,300 $23.1 Million
Q1 2018 May 08, 2018	BUY	$51.15 - $61.0 $3.02 Million - $3.6 Million	59,000 Added 22.56%	320,500 $17.4 Million
Q4 2017 Feb 14, 2018	BUY	$50.85 - $65.1 $12 Million - $15.4 Million	236,500 Added 946.0%	261,500 $15.6 Million
Q3 2017 Nov 15, 2017	BUY	$48.6 - $60.1 $1.22 Million - $1.5 Million	25,000	25,000 $1.22 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.